-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-12-28
Values as of: 2024-12-28
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dorsey Wright? Healthcare Technical Leaders Index (the "underlying index"). The fund generally will invest at least 90% of its total assets in common stocks of companies that comprise the underlying index. The underlying index is composed of at least 30 common stocks of companies in the healthcare sector that have powerful relative strength or "momentum" characteristics.
Company Website : www.invescopowershares.com
Currency: USD
Country : USA
Inception Date: 12/10/2006
Primary Benchmark: Dorsey Wright Hlthcr Tech Ldrs TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.7%
Management Expense Ratio: 0.60 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| LLY | Eli Lilly and Company | 4.75 % |
| INSM | Insmed Inc | 4.29 % |
| NTRA | Natera Inc | 4.20 % |
| PCVX | Vaxcyte Inc | 3.83 % |
| THC | Tenet Healthcare Corporation | 3.43 % |
| ISRG | Intuitive Surgical Inc | 3.06 % |
| HCA | HCA Holdings Inc | 2.85 % |
| ABBV | AbbVie Inc | 2.74 % |
| ADMA | ADMA Biologics Inc | 2.72 % |
| CPRX | Catalyst Pharmaceuticals Inc | 2.71 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 0.47 % |
N/A |
USD 6.53B |
| PPH | VanEck Pharmaceutical ETF | 0.36 % |
N/A |
USD 0.60B |
| BBH | VanEck Biotech ETF | 0.35 % |
N/A |
USD 0.40B |
| PSCH | Invesco S&P SmallCap Health Ca.. | 0.29 % |
N/A |
USD 0.18B |
| GNOM | Global X Genomics & Biotechnol.. | 0.00 % |
N/A |
USD 0.07B |
| FTXH | First Trust Nasdaq Pharmaceuti.. | 0.60 % |
N/A |
USD 0.01B |
| CNCR | Loncar Cancer Immunotherapy ET.. | 0.79 % |
N/A |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| DWTR | 0.00 % | 0.15 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.60% | 75% | C | 56% | F | ||
| Dividend Return | 0.06% | 17% | F | N/A | F | ||
| Total Return | 3.67% | 75% | C | 52% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 3.60% | 75% | C | 56% | F | ||
| Dividend Return | 0.06% | 17% | F | N/A | F | ||
| Total Return | 3.67% | 75% | C | 52% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 27.64% | 88% | B+ | 67% | D+ | ||
| Dividend Return | 0.08% | 14% | F | N/A | F | ||
| Total Return | 27.71% | 88% | B+ | 62% | D | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.63% | 75% | C | 49% | F | ||
| Dividend Return | 3.64% | 75% | C | 45% | F | ||
| Total Return | 0.01% | 13% | F | 1% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 32.29% | 25% | F | 58% | F | ||
| Risk Adjusted Return | 11.26% | 75% | C | 42% | F | ||
| Market Capitalization | 0.07B | 50% | F | 41% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
